"Medizinische Studiengesellschaft Onkologie Nord-West GmbH"
Welcome,         Profile    Billing    Logout  
 2 Trials 
2 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Reichert, Dietmar
NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Checkmark [VIRTUAL] A phase II study of acalabrutinib in combination with R-CHOP chemotherapy prior to autologous stem cell transplantation in previously untreated mantle cell lymphoma
Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), Klinikum der Universitaet Muenchen
Mantle Cell Lymphoma
05/21
05/26
INFINITY, NCT04389541: Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology

Recruiting
N/A
500
Europe
iOMEDICO AG, Bristol-Myers Squibb, Roche Pharma AG
Advanced Solid Tumors or Hematologic Malignancies
06/23
06/23

Download Options